Kopran Limited (KOPRAN) fundamentals
Kopran Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as KOPRAN (ISIN INE082A01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Kopran Limited does
Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.
Valuation and market data
| Last close | ₹237.75 |
|---|---|
| Market capitalisation | ₹1,148 crore |
| Enterprise value | ₹1,160 crore |
| P/E (TTM) | 44.61 |
| Price to book | 2.16 |
| Price to sales (TTM) | 1.00 |
| Book value per share | ₹109.85 |
| Dividend yield | 126.18% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jun 09 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹682 crore | ₹34 crore | ₹26 crore | 5.33 |
| Mar 2025 | ₹634 crore | ₹52 crore | ₹39 crore | 7.99 |
| Mar 2024 | ₹629 crore | ₹68 crore | ₹51 crore | 10.57 |
| Mar 2023 | ₹554 crore | ₹36 crore | ₹27 crore | 5.65 |
| Mar 2022 | ₹488 crore | ₹82 crore | ₹61 crore | 13.77 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 44.4% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 55.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.